NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Derma Sciences, Inc. (“Derma” or the “Company”) (NasdaqCM: DSCI) for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders’ approval for an amendment to the Company’s 2012 Incentive Plan.
Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on April 12, 2013, the Board of Directors recommends that Derma’s shareholders vote to approve an amendment to the Derma Sciences, Inc. 2012 Equity Incentive Plan to increase the number of shares available for issuance thereunder in the amount of 1,687,500 shares. The issuance of the additional shares could have a substantial dilutive effect on the shares of Derma common stock.
Request more information now by clicking here: www.faruqilaw.com/DSCI. There is no cost or obligation to you.
Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.
If you own common stock in Derma and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/DSCI or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.
Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.